Durable response to hormonal therapy in a patient with rapidly progressive low-grade serous ovarian cancer: A case report
This case report describes a 46-year-old patient with rapidly progressive stage IIIA1 estrogen receptor positive low grade serous ovarian cancer (LGSC). She was optimally debulked with no residual disease and received three cycles of adjuvant liposomal doxorubicin and carboplatin intravenous chemoth...
Saved in:
Main Authors: | Catherine H. Watson (Author), Angeles Alvarez Secord (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2020-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Durable response to BRAF inhibitor monotherapy in recurrent metastatic low grade serous ovarian cancer
by: Shashank Sama, et al.
Published: (2024) -
Impressive and durable clinical responses obtained with dabrafenib and trametinib in low-grade serous ovarian cancer harbouring a BRAF V600E mutation
by: Bárbara Lima, et al.
Published: (2022) -
Proteome profiling of low grade serous ovarian cancer
by: Haniyeh Bashi zadeh fakhar, et al.
Published: (2019) -
Binimetinib (MEK162) in recurrent low-grade serous ovarian cancer resistant to chemotherapy and hormonal treatment
by: Chanhee Han, et al.
Published: (2018) -
Low-grade serous carcinoma with extensive osseous metaplasia arising from ovarian serous cystadenofibroma
by: Renan Ribeiro e Ribeiro, et al.
Published: (2021)